CorMedix Inc. (NYSEAMERICAN:CRMD) shares traded up 17.2% during trading on Monday . The company traded as high as $0.67 and last traded at $0.75. 63,850 shares were traded during trading, a decline of 97% from the average session volume of 2,293,307 shares. The stock had previously closed at $0.64.

A number of analysts have recently issued reports on CRMD shares. Zacks Investment Research upgraded CorMedix from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Tuesday, July 31st. HC Wainwright set a $3.00 price objective on CorMedix and gave the company a “buy” rating in a research report on Wednesday, August 15th.

CorMedix (NYSEAMERICAN:CRMD) last released its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.10 million. CorMedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%.

About CorMedix (NYSEAMERICAN:CRMD)

CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.

Further Reading: Buyback For Investors Defined

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.